Literature DB >> 17907099

Beneficial effects of spironolactone on glomerular injury in streptozotocin-induced diabetic rats.

Jun Yuan1, Ruhan Jia, Yan Bao.   

Abstract

INTRODUCTION: To investigate the beneficial effects of spironolactone (SPL) on glomerular injury in streptozotocin (STZ)-induced diabetic rats and the possible mechanism. METHODS AND
RESULTS: STZ-induced diabetic rats were divided into control group, STZ group, and SPL group. Glomerular morphology was observed by light microscopy after the rats were sacrificed after 30 days treatment. The mRNA expressions of transforming growth factor-beta 1 (TGF-beta1) and type-1 plasminogen activator inhibitor (PAI-1) in renal cortex were measured by transcription-polymerase chain reaction (RT-PCR). The protein expressions of PAI-1, fibronectin (FN) and TGF-beta1 were detected by western blotting and immunohistochemistry respectively. In addition, levels of malondialdehyde (MDA) and the activity of antioxidants including superoxide diamutase (SOD), glutathione peroxidase (GSH-PX) in the cortex of kidney were measured.
RESULTS: In untreated diabetic rats, the glomerular volume, the expression of FN and the urinary albumin excretion increased. The mRNA and protein expression of PAI-1 and TGF-beta1 significantly increased in the STZ group. Treatment with SPL partially reversed these changes. Meanwhile, elevated MDA levels as well as decreased SOD and GSH-PX activities in the cortex of kidney were significantly ameliorated in the treated group.
CONCLUSION: SPL ameliorates the glomerular injury in STZ-induced early diabetic renal injury, which is closely related with the reduction of PAI-1 and TGF-beta1 expression and the attenuation of oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17907099     DOI: 10.3317/jraas.2007.014

Source DB:  PubMed          Journal:  J Renin Angiotensin Aldosterone Syst        ISSN: 1470-3203            Impact factor:   1.636


  7 in total

Review 1.  Aldosterone blockade in chronic kidney disease: can it improve outcome?

Authors:  Robert D Toto
Journal:  Curr Opin Nephrol Hypertens       Date:  2010-09       Impact factor: 2.894

2.  Spironolactone inhibits apoptosis in rat mesangial cells under hyperglycaemic conditions via the Wnt signalling pathway.

Authors:  Dan Zhu; Hongwei Yu; Hongjiang He; Jiuli Ding; Jie Tang; Dan Cao; Lirong Hao
Journal:  Mol Cell Biochem       Date:  2013-04-29       Impact factor: 3.396

Review 3.  Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects.

Authors:  Jonatan Barrera-Chimal; Ixchel Lima-Posada; George L Bakris; Frederic Jaisser
Journal:  Nat Rev Nephrol       Date:  2021-10-21       Impact factor: 28.314

Review 4.  The necessity and effectiveness of mineralocorticoid receptor antagonist in the treatment of diabetic nephropathy.

Authors:  Atsuhisa Sato
Journal:  Hypertens Res       Date:  2015-03-12       Impact factor: 3.872

Review 5.  Chronic kidney disease: a new look at pathogenetic mechanisms and treatment options.

Authors:  Damien Noone; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2013-03-08       Impact factor: 3.714

6.  Aldosterone signaling regulates the over-expression of claudin-4 and -8 at the distal nephron from type 1 diabetic rats.

Authors:  Eduardo Molina-Jijón; Rafael Rodríguez-Muñoz; Ricardo González-Ramírez; Carmen Namorado-Tónix; José Pedraza-Chaverri; Jose L Reyes
Journal:  PLoS One       Date:  2017-05-11       Impact factor: 3.240

Review 7.  Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease.

Authors:  Nina Vodošek Hojs; Sebastjan Bevc; Robert Ekart; Nejc Piko; Tadej Petreski; Radovan Hojs
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.